Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Nivolumab, ipilimumab and panitumumab in mCRC

Stacey Cohen • 28 Jun 2020
ESMO WCGIC 2020
Colorectal Cancer Gastrointestinal Cancer Antibodies Ipilimumab Nivolumab Panitumumab

Stacey Cohen, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the rationale and study design of a Phase II clinical trial investigating the clinical efficacy of nivolumab, ipilimumab, and panitumumab in patients with unresectable refractory KRAS/NRAS/BRAF wild-type microsatellite stable metastatic colorectal cancer (mCRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Stacey Cohen

0:31
Highlights in colorectal cancer at ASCO GI 2023
Stacey Cohen • 20 Jan 2023
0:59
Practical considerations for genomic testing in colorectal cancer
Stacey Cohen • 20 Jan 2023
2:17
Does postoperative cfDNA affect MRD detection rates in CRC?
Stacey Cohen • 20 Jan 2023
0:31
Applications of ctDNA in the management of colorectal cancer
Stacey Cohen • 20 Jan 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals